Compare · ARGX vs TTNP
ARGX vs TTNP
Side-by-side comparison of argenx SE (ARGX) and Titan Pharmaceuticals Inc. (TTNP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and TTNP operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $55.32B, about 5497.2x TTNP ($10.1M).
- Over the past year, ARGX is up 52.8% and TTNP is up 1.3% - ARGX leads by 51.5 points.
- ARGX has hit the wire 5 times in the past 4 weeks while TTNP has been quiet.
- ARGX has more recent analyst coverage (25 ratings vs 0 for TTNP).
- Company
- argenx SE
- Titan Pharmaceuticals Inc.
- Price
- $891.80+5.79%
- $6.29+53.04%
- Market cap
- $55.32B
- $10.1M
- 1M return
- +10.56%
- +21.63%
- 1Y return
- +52.81%
- +1.27%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 0
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Titan Pharmaceuticals Inc.
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program, TP-2021 for use in combination with ProNeura technology for treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including non-clinical evaluation of the ProNeura platform in malaria prophylaxis. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based in South San Francisco, California.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest TTNP
- SEC Form EFFECT filed by Titan Pharmaceuticals Inc.
- SEC Form EFFECT filed by Titan Pharmaceuticals Inc.
- SEC Form EFFECT filed by Titan Pharmaceuticals Inc.
- SEC Form EFFECT filed by Titan Pharmaceuticals Inc.
- SEC Form EFFECT filed by Titan Pharmaceuticals Inc.
- SEC Form EFFECT filed by Titan Pharmaceuticals Inc.
- SEC Form 15-12G filed by Titan Pharmaceuticals Inc.
- SEC Form POS AM filed by Titan Pharmaceuticals Inc.
- SEC Form S-8 POS filed by Titan Pharmaceuticals Inc.
- SEC Form S-8 POS filed by Titan Pharmaceuticals Inc.